唾液 miR-21、-155 和-375 对口腔鳞状细胞癌患者的临床意义。

CLINICAL SIGNIFICANCE OF SALIVARY MIR-21, -155, AND -375 IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF ORAL CAVITY.

机构信息

Nonprofit organization "National Cancer Institute", Kyiv, Ukraine.

R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the NASU, Kyiv, Ukraine.

出版信息

Exp Oncol. 2024 Oct 9;46(2):139-145. doi: 10.15407/exp-oncology.2024.02.139.

DOI:10.15407/exp-oncology.2024.02.139

PMID:39396170

Abstract

BACKGROUND

The current prognostic markers in oral squamous cell carcinoma (OSCC) have limited accuracy sometimes leading to inappropriate treatment decisions. Identifying new markers would help clinicians tailor treatment plans based on the individual patient risk factors leading to improved survival rates and quality of life.

AIM

To estimate the value of the miRNA expression indicators in saliva as prognostic and predictive markers of the effectiveness of neoadjuvant chemotherapy (NACT).

MATERIALS AND METHODS

The work is based on the results of the examination and treatment of 61 patients with stage II-IV OSCC. The miR-21, miR-155, and miR-375 expression levels in the saliva samples were analyzed by the real-time reverse transcription polymerase chain reaction.

RESULTS

The salivary miR-21 and -155 expression levels in healthy volunteers were 2.49 and 2.84 times lower than in OSCС patients (p < 0.05). The positive association of miR-21 and miR-155 expression levels and the negative correlation of miR-375 expression level with T index by TNM (r = 0.68, r = 0.75, and r = -0.67, respectively) (p < 0.05) and the presence of lymph node metastasis (r = 0.78, r = 0.71, and r = ‒0.59, respectively) (p < 0.05) were found. Patients with good response to NACT had lower miR-21 and -155, and higher miR-375 levels in saliva compared to those with resistant tumors.

CONCLUSIONS

Our study suggests that salivary miR-21, miR-155, and miR-375 may be potential biomarkers for the prognosis of cancer course and the response to NACT in OSCC patients.

摘要

背景

口腔鳞状细胞癌（OSCC）目前的预后标志物有时准确性有限，导致治疗决策不当。识别新的标志物将有助于临床医生根据个体患者的风险因素制定治疗计划，从而提高生存率和生活质量。

目的

评估唾液中 miRNA 表达指标作为新辅助化疗（NACT）疗效的预后和预测标志物的价值。

材料和方法

该研究基于对 61 例 II-IV 期 OSCC 患者的检查和治疗结果。通过实时逆转录聚合酶链反应分析唾液样本中 miR-21、miR-155 和 miR-375 的表达水平。

结果

健康志愿者唾液中的 miR-21 和 miR-155 表达水平分别比 OSCС 患者低 2.49 和 2.84 倍（p<0.05）。miR-21 和 miR-155 表达水平与 TNM 的 T 指数呈正相关（r=0.68、r=0.75），miR-375 表达水平与 T 指数呈负相关（r=-0.67）（p<0.05），且与淋巴结转移有关（r=0.78、r=0.71、r=-0.59）（p<0.05）。与对 NACT 耐药的肿瘤患者相比，对 NACT 反应良好的患者唾液中的 miR-21 和 miR-155 水平较低，miR-375 水平较高。